Synergistic SGLT2 and GLP-1R targeting alleviates systemic inflammation-induced and M1 monocyte-driven endothelial dysfunction in coronary artery disease
Combining two drugs that target different pathways synergistically reduces inflammation in heart disease, providing mechanistic rationale for combination therapy.
Using ex vivo CAD specimens and in vitro monocyte/endothelial models, this study found that simultaneous SGLT2 and GLP-1R targeting synergistically alleviated systemic inflammation-induced endothelial dysfunction driven by M1 monocyte activation. The findings provide mechanistic rationale for combination SGLT2i/GLP-1RA therapy in CAD patients and identify specific anti-inflammatory pathways mediating the cardioprotective synergy.
What the study was
- Study design
- Mechanistic study with ex vivo CAD patient tissue and in vitro monocyte/endothelial co-culture models
- Population
- Ex vivo CAD patient coronary tissue and in vitro monocyte/endothelial models
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Cardiovasc Diabetol
Why it surfaced
Cardiovasc Diabetol mechanistic study with ex vivo CAD patient tissue supporting SGLT2i+GLP-1RA synergy via M1 monocyte suppression; relevant to cardiometabolic combination therapy rationale.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.